MBRX Moleculin Biotech Inc.

Moleculin Biotech Inc is a preclinical stage pharmaceutical company. The company is engaged in the development of anti-cancer drug candidates. Its drug development technologies include liposomal Annamycin, WP1122 and WP1066.

As of 11/26/2021     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  06/02/2016
Outstanding shares:  28,577,088
Average volume:  247,784
Market cap:   $62,869,594
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    60855D200
ISIN:        US60855D2009
Valuation   (See tab for details)
PE ratio:   -4.70
PB ratio:   0.76
PS ratio:   0.00
Return on equity:   -19.33%
Net income %:   -12,175,968.99%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy